Drug Information

Drug General Information
Drug ID
D03IIS
Former ID
DNC001373
Drug Name
SR-45023A (Apomine)
Drug Type
Small molecular drug
Indication Discovery agent Investigative [535129]
Structure
Download
2D MOL

3D MOL
Formula
C28H52O7P2
Canonical SMILES
CC(C)OP(=O)(C(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)<br />(OC(C)C)OC(C)C)OC(C)C
InChI
1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3
InChIKey
YLJOVCWVJCDPLN-UHFFFAOYSA-N
CAS Number
CAS 126411-13-0
PubChem Compound ID
176405
PubChem Substance ID
10258374, 12014463, 14812926, 33500021, 53681178, 57395304, 104425545, 129812401, 134223669, 135153618, 137267077, 137783358, 198985894, 227837930
Target and Pathway
Target(s) Bile acid receptor Target Info Agonist [535129]
KEGG Pathway Bile secretion
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptor
Reactome Recycling of bile acids and salts
PPARA activates gene expression
Endogenous sterols
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity
Nuclear Receptors Meta-Pathway
Farnesoid X Receptor Pathway
Drug Induction of Bile Acid Pathway
References
Ref 535129The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
Ref 535129The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.